GSK to scrap sales reps targets and payments to doctors
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline says it is making major changes to its global sales and marketing practices "to further ensure patient interests come first". Its sales reps will no longer have individual sales targets and it will "modernize" its relationship with doctors by ceasing payments for speaking arrangements or attendance at medical conferences. However, this latter move will take until 2016 to become effective.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.